Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, […]
Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American […]
Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program GDT201 Utrecht, Netherlands and Boston, Mass., 15 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer […]
